Landos Biopharma announces strategic research collaboration with KU Leuven

Landos Biopharma announced a strategic research collaboration to investigate the effects of NX-13 on epithelial cells with the Inflammatory Bowel Disease Team at KU Leuven and University Hospitals Leuven, a leading European research university and hospital network known for its innovation in Leuven, Belgium. The NEXUS Phase 2 proof-of-concept clinical trial of NX-13 in patients with moderate-to-severe ulcerative colitis was initiated during the second quarter of 2023. Recruitment, screening and randomization of patients continues, with top-line results on track for the fourth quarter of 2024. The results are expected to provide further insight into the impact of NX-13 on gene expression and regulation, and cytokine responses. “We are thrilled to collaborate with Dr. Verstockt and the IBD Team at KU Leuven, an established global research center at the leading edge of clinical and translational research,” commented Dr. Fabio Cataldi, Executive Vice-President & Chief Medical Officer at Landos. “We expect this research will broaden our already strong data foundation for the novel and unique bimodal mechanism of action of NX-13 and further validate the role of immunometabolism in inflammation and IBD.”